ReviewFrontiers in neurology
Epigenetic equilibrium in chromatinopathies: network instability in neurodevelopment.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chromatin-modifying systems regulate transcriptional programs essential for human neurodevelopment through dynamic modification of histones, DNA, and higher-order chromatin architecture. Pathogenic variants affecting these systems give rise to chromatinopathies, a heterogeneous group of disorders characterised by consistent neurological features, including intellectual disability, developmental delay, autism spectrum disorder, epilepsy, and language impairment, alongside directional variation in somatic traits such as growth and skeletal development. This discordance challenges linear genotype-phenotype models. Methods: This conceptual review synthesises genetic, epigenomic, transcriptomic, cellular, neuroimaging, and electrophysiological evidence to develop an epigenetic equilibrium model. The model proposes that neurodevelopment depends on context-specific balance among activation-associated and repressive chromatin mechanisms. Deviation from this range disrupts transcriptional fidelity and neural network stability. The concepts of chromatin load, network capacity, and mirror endophenotyping are used to explain variable expressivity, direction-sensitive somatic phenotypes, and convergent neurological outcomes. Results: Despite molecular diversity, chromatinopathies converge neurologically due to disruption of transcriptional equilibrium. We introduce an epigenetic equilibrium model incorporating chromatin load, network capacity, and transcriptional dynamics. We further define mirror endophenotyping as a framework capturing reciprocal directionality of intermediate phenotypes across shared chromatin axes. Conclusion: Chromatinopathies are best understood as systems-level disorders of transcriptional regulation rather than isolated molecular defects. This framework provides a unifying mechanistic explanation for phenotypic convergence across chromatinopathies and introduces a systems-level approach to diagnosis and therapy. This approach provides a foundation for precision neurology in neurodevelopmental disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.